Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, Research & Development | June 03, 2019 | June 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date June 03, 2019 · Filed June 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $15.17 · Expires 2029-06-03 | Direct | 129,358 |
Reported balance
After 2019-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-03 · Grant · Acquired 129,358 · Balance 129,358 F1: This option vests one-fourth on such date and 1/48 monthly thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-06-03 | Direct | 65,920 |
Reported balance
After 2019-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-03 · Grant · Acquired 65,920 · Balance 65,920 F2: This award vests one-fourth on such date and one-fourth on each anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests one-fourth on such date and 1/48 monthly thereafter.
F2: This award vests one-fourth on such date and one-fourth on each anniversary thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENDOCYTE INC
Report date December 21, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,753 |
Reported balance
After 2018-12-20 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2018-12-20 · Gift · Disposed 10,500 · Balance 139,753 F1: Represents a gift of 10,500 shares by the reporting person to her daughter, who shares the reporting person's household. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2018-12-21 · Disposition to issuer · Disposed 72,253 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2018-12-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: This restricted stock unit ("RSU") award, which originally consisted of 20,000 RSUs and of which 15,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on July 31, 2016 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2018-12-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: This RSU award, which originally consisted of 10,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 7
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 7 · 2018-12-21 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: This RSU award, which originally consisted of 20,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 8
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 8 · 2018-12-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 9
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 9 · 2018-12-21 · Disposition to issuer · Disposed 22,500 · Balance 0 F7: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 10,500 |
Reported balance
After 2018-12-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-12-20 · Gift · Acquired 10,500 · Balance 10,500 F1: Represents a gift of 10,500 shares by the reporting person to her daughter, who shares the reporting person's household. |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 0 |
Reported balance
After 2018-12-21 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-12-21 · Disposition to issuer · Disposed 10,500 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2025-07-31 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-12-21 · Disposition to issuer · Disposed 25,000 · Balance 0 F8: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on July 31, 2016. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.18 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-12-21 · Disposition to issuer · Disposed 45,788 · Balance 0 F9: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.16 · Expires 2027-02-02 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-12-21 · Disposition to issuer · Disposed 39,999 · Balance 0 F10: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2028-02-08 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-12-21 · Disposition to issuer · Disposed 45,000 · Balance 0 F11: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a gift of 10,500 shares by the reporting person to her daughter, who shares the reporting person's household.
F2: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
F3: This restricted stock unit ("RSU") award, which originally consisted of 20,000 RSUs and of which 15,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on July 31, 2016 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F4: This RSU award, which originally consisted of 10,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F5: This RSU award, which originally consisted of 20,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F6: This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F7: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F8: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on July 31, 2016. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
F9: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
F10: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
F11: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 4, 2019 20:44 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 65,920 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007125 · edgar.xml · derivative · entry 2 Armour Alison A. · CIK 0001646726 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,920 Underlying: Common Stock · 65,920 shares Expires 2029-06-03 F2 · derivative.exercise_date: This award vests one-fourth on such date and one-fourth on each anniversary thereafter. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 20:44 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOptions to Purchase Common Stock · Derivative | 129,358 | $0.00 Strike: $15.17 | $0.00 |
DisclosureSEC source: 0001179110-19-007125 · edgar.xml · derivative · entry 1 Armour Alison A. · CIK 0001646726 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,358 Underlying: Common Stock · 129,358 shares Expires 2029-06-03 F1 · derivative.exercise_date: This option vests one-fourth on such date and 1/48 monthly thereafter. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 45,000 | $20.99 Strike: $3.01 | $944,550.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · derivative · entry 13 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2028-02-08 F11 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F11 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 8, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 39,999 | $21.84 Strike: $2.16 | $873,578.16 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · derivative · entry 12 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,999 shares Expires 2027-02-02 F10 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F10 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 45,788 | $20.82 Strike: $3.18 | $953,306.16 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · derivative · entry 11 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,788 shares Expires 2026-02-04 F9 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F9 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 4, 2017. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | $18.84 Strike: $5.16 | $471,000.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · derivative · entry 10 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-07-31 F8 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on July 31, 2016. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F8 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on July 31, 2016. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 22,500 | $24.00 | $540,000.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 9 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F7 · price: This RSU award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 8, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 20,000 | $24.00 | $480,000.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 8 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · price: This RSU award, which originally consisted of 40,000 RSUs and of which 20,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/2 annually over a period of 2 years beginning on October 4, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 15,000 | $24.00 | $360,000.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 7 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · price: This RSU award, which originally consisted of 20,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 2, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 5,000 | $24.00 | $120,000.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 6 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: This RSU award, which originally consisted of 10,000 RSUs and of which 5,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 4, 2017 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 5,000 | $24.00 | $120,000.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 5 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: This restricted stock unit ("RSU") award, which originally consisted of 20,000 RSUs and of which 15,000 RSUs had vested and been settled as of immediately prior to the Effective Time, provided for vesting and settlement 1/4 annually over a period of 4 years beginning on July 31, 2016 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 10,500 | $24.00 | $252,000.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 4 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 0 F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 72,253 | $24.00 | $1,734,072.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 3 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | GiftCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 2 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 10,500 F1 · price: Represents a gift of 10,500 shares by the reporting person to her daughter, who shares the reporting person's household. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | GiftCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-074356 · a4.xml · nonDerivative · entry 1 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,753 F1 · price: Represents a gift of 10,500 shares by the reporting person to her daughter, who shares the reporting person's household. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:13 UTC | ENDOCYTE INC ECYT · Entity 161591 | Exercise / conversionStock option (right to buy) · Derivative | 1 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001179110-18-014134 · edgar.xml · derivative · entry 6 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,999 Underlying: Common Stock · 1 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to this option vest 1/4 annually over a period of four years beginning February 2, 2018. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:13 UTC | ENDOCYTE INC ECYT · Entity 161591 | Exercise / conversionStock option (right to buy) · Derivative | 14,212 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001179110-18-014134 · edgar.xml · derivative · entry 5 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,788 Underlying: Common Stock · 14,212 shares Expires 2026-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:13 UTC | ENDOCYTE INC ECYT · Entity 161591 | Exercise / conversionStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001179110-18-014134 · edgar.xml · derivative · entry 4 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 35,000 shares Expires 2025-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to this option vest 1/4 annually over a period of four years beginning July 31, 2016. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:13 UTC | ENDOCYTE INC ECYT · Entity 161591 | Exercise / conversionCommon Stock | 1 | $2.16 | $2.16 |
DisclosureSEC source: 0001179110-18-014134 · edgar.xml · nonDerivative · entry 3 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:13 UTC | ENDOCYTE INC ECYT · Entity 161591 | Exercise / conversionCommon Stock | 14,212 | $3.18 | $45,194.16 |
DisclosureSEC source: 0001179110-18-014134 · edgar.xml · nonDerivative · entry 2 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 16:13 UTC | ENDOCYTE INC ECYT · Entity 161591 | Exercise / conversionCommon Stock | 35,000 | $5.16 | $180,600.00 |
DisclosureSEC source: 0001179110-18-014134 · edgar.xml · nonDerivative · entry 1 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 14:21 UTC | ENDOCYTE INC ECYT · Entity 161591 | SaleCommon Stock | 9,111 | $15.56 | $141,748.03 |
DisclosureSEC source: 0001179110-18-012092 · edgar.xml · nonDerivative · entry 1 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,040 F1 · shares: Represents the sale of 9,111 shares in multiple transactions, ranging in price from $15.1400 to $15.9150, resulting in a weighted-average sale price per share of $15.5579. The 9,111 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 20,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold by Merrill Lynch pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934 adopted by the reporting person on August 1, 2018. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:05 UTC | ENDOCYTE INC ECYT · Entity 161591 | SaleCommon Stock | 1,414 | $15.98 | $22,589.50 |
DisclosureSEC source: 0001179110-18-010127 · edgar.xml · nonDerivative · entry 1 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,151 F1 · shares: Represents the sale of 1,414 shares in multiple transactions, ranging in price from $15.9600 to $16.0500, resulting in a weighted-average sale price per share of $15.9756. The 1,414 shares were sold to cover taxes, commissions and fees associated with the July 31, 2018 settlement of 5,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold by Merrill Lynch pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934 adopted by the reporting person on August 1, 2018. Read SEC document |
| February 08, 2018 Filed Feb 8, 2018 16:43 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001179110-18-001809 · edgar.xml · derivative · entry 2 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-02-08 F2 · derivative.exercise_date: Shares subject to the option vest 1/4 annually over a period of 4 years beginning on 2/8/19. Read SEC document |
| February 08, 2018 Filed Feb 8, 2018 16:43 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001809 · edgar.xml · nonDerivative · entry 1 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,565 F1 · shares: Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on 2/8/19 in the form of one share of common stock for each restricted stock unit. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 17:08 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-013183 · edgar.xml · nonDerivative · entry 1 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,065 F1 · shares: Represents restricted stock units that will vest and be paid 1/2 annually over a period of 2 years beginning on October 4, 2018, in the form of one share of common stock for each restricted stock unit. Read SEC document |
| February 04, 2017 Filed Feb 7, 2017 19:26 UTC | ENDOCYTE INC ECYT · Entity 161591 | Tax withholdingCommon Stock | 935 | $2.18 | $2,038.30 |
DisclosureSEC source: 0001179110-17-001933 · edgar.xml · nonDerivative · entry 1 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,065 F1 · shares: Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 2,500 restricted stock units in the form of Company common stock on a one-for-one basis on February 4, 2017. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 15:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001179110-17-001598 · edgar.xml · derivative · entry 2 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-02-02 F2 · derivative.exercise_date: Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 2, 2018. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 15:49 UTC | ENDOCYTE INC ECYT · Entity 161591 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001598 · edgar.xml · nonDerivative · entry 1 Armour Alison A. · CIK 0001646726 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 2, 2018, in the form of one share of common stock for each restricted stock unit. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.